Skip to content
WeighLab
Menu

Head-to-head · Cost-Efficiency Index

Näky vs 24hrDOC

Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.

Better valueGrade C · #290

Näky

Shoppers who want a distinct oral semaglutide drops product and a separate GLP-1 microdose option.

Visit Näky
VS
Grade C · #296

24hrDOC

Shoppers comparing the ongoing standing price of compounded GLP-1s, not the first-month promotional rate.

Visit 24hrDOC

The verdict

Winner · NäkyGrade C vs C

Näky takes it, leading the Cost-Efficiency Index 58 to 57. Näky (benaky.com) is a LegitScript-verified compounded GLP-1 telehealth platform whose marketing pages disclose no pricing, but whose public Shopify product feed shows real flat prices: $145 for compounded semaglutide injections. 24hrDOC still earns a CShoppers comparing the ongoing standing price of compounded GLP-1s, not the first-month promotional rate.

Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Näky.

Factor by factor

Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.

Normalized Cost/Month

78
48

Price Transparency

30
78

Nationwide Access

24
24

Formulation Options

90
77

Clinical Oversight

76
68

Contract Flexibility

55
55

Pricing, coverage & formulary

The disclosed facts behind the scores. Lower price wins its row (teal).

SpecNäky24hrDOC
Cost-Efficiency Index58/10057/100
Semaglutide / mo$145/mo (compounded)$249/mo (microdose tier, 2 mg dose, compounded)
Tirzepatide / mo$265/mo (compounded)$339/mo (microdose tier, starting dose, compounded)
Semaglutide / yr (modeled)$1,740$2,988
Tirzepatide / yr (modeled)$3,180$4,068
CoverageCoverage not publishedCoverage not published
Oral / sublingualYesYes
Brand-name accessYesCompounded only
Rank here#290#296

Näky

58/100

Where the value is

  • Distinct oral semaglutide drops product line ($145) as an alternative to injections — uncommon among compounded GLP-1 brands
  • Separate GLP-1 microdose program offered ($185) for patients who want a lower-dose protocol
  • LegitScript verification is displayed and checkable for the benaky.com domain

The tradeoffs

  • No pricing is shown on any customer-facing marketing page — every page checked (homepage, /pricing, /shop, /tirzepatide, /oral-semaglutide, /weight-loss, /pages/faq) either 404'd or omitted dollar figures; prices had to be pulled from a developer-facing JSON feed, not something a typical visitor would find
  • A 'Wegovy® Pill' SKU at $149 borrows Novo Nordisk's registered brand name for what does not appear to be an FDA-approved oral Wegovy product — this needs independent verification before being treated as genuine branded access
Visit Näky

Full Näky review →

24hrDOC

57/100

Where the value is

  • Full struck-through pricing (promo vs. regular) is published on-site before intake, so the true ongoing cost is verifiable rather than hidden
  • Both standard and lower-cost microdose options published for each drug
  • Fast intake model: '10-minute assessment' with no office visit required

The tradeoffs

  • The widely-advertised $149/$239 price is a ONE-TIME first-month discount ('$100 off'); the standing ongoing price is $249/mo semaglutide and $339/mo tirzepatide — about 40% higher
  • No compounding pharmacy or medical director named on the site
Visit 24hrDOC

Full 24hrDOC review →

Regulatory note: the FDA issued a warning letter to 24HrDoc, Inc. dba 24HrDoc in February 2026. We still list and link to 24hrDOC; you should know the letter is on the public record before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.

Keep comparing

← All head-to-head comparisons